Study of a HER3 antibody with cetuximab and possibly docetaxel
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1/2 trial tests whether an antibody that targets HER3 (with cetuximab, and possibly docetaxel) can help treat advanced squamous cell cancers that have already been treated or cannot use standard options. It mainly looks at safety first, and also whether the treatment can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to read, understand, and sign the consent form
- Have advanced squamous cell cancer that fits the study’s cancer types and stage (or has specific prior treatments)
- Your cancer must have at least one measurable spot on scans
- Be able and willing to do a fresh tumor biopsy before starting the study
- Have overall health good enough for treatment (including “ECOG” status 0 to 1 and adequate organ function)
- Be able to use strong birth control and not be pregnant or breastfeeding (for the required sex at birth rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SIBP-03 for people with head and neck squamous cell carcinoma that has come back or spread. It is for those whose cancer has worsened after prior immunotherapy and platinum chemotherapy, and who have no option for curative local treatment.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial tests a combination of three drugs (cetuximab, tislelizumab, and chemotherapy) in people with advanced head and neck cancer that hasn't been treated before. The goal is to see if this mix can shrink tumors and improve outcomes.
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Hear when a new Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.